^
Association details:
| Biomarker: | FGFR2 fusion |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | derazantinib (ARQ 087) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1/2 Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors with FGFR Genetic Alterations Studio di fase I/II con ARQ 087 in soggetti adulti con Tumori solidi in stadio avanzato che presentino alterazione genetica FGFR
Excerpt:
...All subjects eligible for enrollment in the Expanded Cohort must have documented and/or confirmed FGFR genetic alterations, including iCCA with FGFR2 gene fusion. ...
Trial ID:
Source:
Title:
541P - Derazantinib (DZB), an oral fibroblast growth factor receptor inhibitor (FGFRi), shows promising activity in PDX-tumour models with aberrations in FGFR1-3
Published date:
09/14/2020
Excerpt:
In GC models, known FGFR driver mutations were associated with partial responses (best dT/C=0.42), however models carrying FGFR2-fusions (4/6 with FGFR fusions) were highly responsive leading to strong regressions….DZB had strong activity in PDX-models with FGFR-fusions and high FGFR expression, in particular in GC, where regressions were observed in all FGFR2 fusion models...
